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mdx mouseExcessive extracellular matrix deposition progressively replacing muscle ﬁbres is the endpoint of most severe
muscle diseases. Recent data indicate major involvement of microRNAs in regulating pro- and anti-ﬁbrotic genes.
To investigate the roles of miR-21 and miR-29 in muscle ﬁbrosis in Duchenne muscle dystrophy, we evaluated
their expression inmuscle biopsies from14patients, and inmuscle-derivedﬁbroblasts andmyoblasts. In Duchenne
muscle biopsies, miR-21 expression was signiﬁcantly increased, and correlated directly with COL1A1 and COL6A1
transcript levels. MiR-21 expression was also signiﬁcantly increased in Duchenne ﬁbroblasts, more so after TGF-
β1 treatment. In Duchenne ﬁbroblasts the expression of miR-21 target transcripts PTEN (phosphatase and tensin
homolog deleted on chromosome 10) and SPRY-1 (Sprouty homolog 1) was signiﬁcantly reduced; while collagen
I and VI transcript levels and soluble collagen production were signiﬁcantly increased. MiR-29a and miR-29c were
signiﬁcantly reduced in Duchenne muscle and myoblasts, and miR-29 target transcripts, COL3A1, FBN1 and YY1,
signiﬁcantly increased. MiR-21 silencing in mdx mice reduced ﬁbrosis in the diaphragm muscle and in both
Duchenne ﬁbroblasts and mdx mice restored PTEN and SPRY-1 expression, and signiﬁcantly reduced collagen I
and VI expression; while miR-29 mimicking in Duchenne myoblasts signiﬁcantly decreased miR-29 target
transcripts. These ﬁndings indicate that miR-21 and miR-29 play opposing roles in Duchenne muscle ﬁbrosis and
suggest that pharmacological modulation of their expression has therapeutic potential for reducing ﬁbrosis in
this condition.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
In severe muscular dystrophies such as congenital muscular dystro-
phies and Duchenne muscular dystrophy (DMD), the primary defect
leads to continuous myoﬁbre injury and degeneration. In DMD, chronic
muscle tissue damage and inﬂammatory inﬁltrates persist, resident sat-
ellite cells are unable to keep pace with the requirement for new ﬁbres,
and ﬁbrogenic cells are continuously activated, eventually leading to
massive connective tissue deposition (ﬁbrosis) [41]. In addition to im-
peding ﬁbre regeneration, ﬁbrosis may obstruct the targeting of speciﬁcL1A1, collagen type I alpha 1;
alpha1;DMD,Duchennemuscle
signal-regulated kinase; FBN1,
s,microRNAs; PAI-1, plasmino-
molog deleted on chromosome
wth factor-β1; TWF1, twinﬁlin-
tional Neurological Institute “C.
o, Italy. Tel.: +39 022394632;therapies (drugs or cells) to muscle, and worsen disease progression by
obstructing nutrient delivery.
Fibrosis is not a peculiarity of DMD and chronic myopathies, but
characterizes diseases of various tissues, including lung [40], liver [20],
kidney [39], heart [22], skin [42], and bladder [11].
Fibroblasts play a major role in ﬁbrosis. Normally they are involved
in the repair response to injury by secreting proteins of the extracellular
matrix (ECM) and growth factors, and by differentiating into contractile
and secretory myoﬁbroblasts, characterized by α-smooth muscle actin
(α-SMA) expression and active ECM synthesis [29]. The cytokine TGF-
β1 is also a major player in ﬁbrosis and in particular induces differenti-
ation of ﬁbroblasts to myoﬁbroblasts [10]. In ﬁbrotic conditions in gen-
eral, myoﬁbroblasts remain at injury sites where they secrete ECM
proteins in excess to thereby severely impair tissue function.
Our previous study showed that primary ﬁbroblasts derived from
DMD muscles have a pro-ﬁbrotic phenotype probably due to intrinsic
memory of their native environment, which is altered by the primary
genetic defect [54,55]. We have also shown that transcript expression
and protein modulation of several ECM components are altered in
DMD myotubes [58]. These ﬁndings indicate that both myogenic cells
and resident ﬁbroblasts contribute to ﬁbrosis in DMD skeletal muscle,
and to elucidate the molecular mechanisms of the ﬁbrotic process it is
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blast cell lineages.
MicroRNAs (miRNAs) are small non-coding RNAmolecules found in
plants and animals, whose main function seems to be to downregulate
gene expression by various mechanisms, including, translation repres-
sion, and mRNA cleavage and deadenylation. Recent evidence indicates
that miRNAs also play fundamental roles in other biological and also
pathological processes. In particular, aberrant expression of miRNAs
has been related to the development of ﬁbrosis in various tissues
through regulation of anti- and pro-ﬁbrotic genes [5].
MiR-21 was originally considered an oncomiR, as it is over-expressed
in most cancer types [27], but recent data show that it is one of the most
highly upregulated miRNAs during tissue injury, and that its persistent
overexpression disrupts tissue repair and contributes to tissue ﬁbrosis
in heart [6], kidney [12], liver [32] and lung [23].MiR-21 is also upregulat-
ed during the wound contraction and collagen deposition phases of skin
wound healing [48], and promotes keratinocyte migration by inhibiting
TIMP-3 [52]. MiR-21 is rapidly induced by TGF-β1 treatment, suggesting
that it may be involved in the pro-ﬁbrotic effects of TGF-β1 [5]. Finally, in
mice with experimentally-induced or age-associated (mdx) muscle ﬁ-
brosis, miR-21 biogenesis is regulated by the extracellular PAI-1/
plasmin system [3].
Recent studies have also shown that themiR-29 family of miRNAs is
involved in heart, liver, lung, and skin ﬁbrosis [9,16,37,44]. MiR-29
downregulates the expression of ECM components collagens, ﬁbrillins
and elastin, while its downregulation in the dystrophic muscles of
mdx mice not only results in impaired regeneration, but also directly
contributes to muscle ﬁbrosis [47]. MiR-29 also inhibits TGF-β1
induced-transdifferentiation of myoblasts into myoﬁbroblasts [59].
These ﬁndings suggest that miR-29 miRNAs have an anti-ﬁbrotic role.
In view of the emerging roles of miR-21 and miR-29 in ﬁbrotic disor-
ders, we evaluated their expression in DMD and control muscle biopsies.
We also analysedmiR-21 expression in DMD and controlmuscle-derived
ﬁbroblast cultures (since preliminary studies, not presented, indicated
that miR-21 is predominantly expressed in this cell lineage) and miR-
29 expression in myoblast cultures (since our preliminary data indicate
that miR-29 is predominantly expressed in these cells). We assessed
the expression of these miRNAs in cultures treated and not treated with
TGF-β1.
To further probe the roles of miR-21 and miR-29 in muscle ﬁbrosis,
we investigated expression levels of miR-21 and miR-29 targets before
and after cell transfection with miR-21 inhibitor in DMD ﬁbroblasts,
and miR-29 mimics in DMDmyoblasts, respectively.
We also examined the PAI-1/plasmin system in ﬁbroblasts since we
have previously shown that muscle-derived ﬁbroblasts from DMD pa-
tients are ﬁbrogenic [54,55] and the system is involved in ECM remod-
elling and regulation of miR-21 biogenesis [3]. Finally, to assess the
therapeutic potential of miR-21 inhibition, we treated mdx mice with
antagomiR-21.
2. Materials and methods
2.1. Muscle biopsies and cell cultures
Quadriceps muscle biopsies were obtained after informed parental
consent from 14 DMD patients (age 1–8 years; no one has ever been
under steroid treatment), 5 patients with congenital muscular dystro-
phy 1A (MDC1A) as positive controls (age 1 month–3 years) and 11
age-matched controls (age 1–7 years) with suspected neuromuscular
disease, but normal muscle on biopsy. Investigations on human tissue
were approved by our institutional review board and were in accor-
dancewith the Italian law. DMD andMDC1Awere diagnosed by dystro-
phin/laminin alpha2 chain testing and gene analysis.
Fibroblasts and myoblasts were obtained from three DMD patients
(aged 2–6 years) and three age-matched controls (age 3–4 years), by
immunomagnetic selection from primary muscle biopsy-derived cellcultures, as described elsewhere [58]. Fibroblasts were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM; Lonza Group Ltd, Basel,
Switzerland), supplemented with 10% heat-inactivated foetal bovine
serum (FBS; Gibco Life Technologies, Carlsbad, CA, USA), 1% penicillin–
streptomycin (Lonza), and 2 mM L-glutamine (Lonza).
Myoblasts were cultured in DMEM supplemented with 20% FBS, 1%
penicillin–streptomycin, 2 mM L-glutamine, 10 μg/ml insulin (Sigma
Aldrich, St. Louis, MO, USA), 2.5 ng/ml basic ﬁbroblast growth factor
(bFGF; Gibco), and 10 ng/ml epidermal growth factor (EGF; Gibco). Ex-
periments were performed on early passages (3–10 passages) of normal
and dystrophic ﬁbroblasts and myoblasts.
Control and DMD ﬁbroblasts and myoblasts were treated with
10 ng/ml h-recombinant TGF-β1 (Peprotech EC, London, UK) for 48 h,
as described previously [55].
2.2. Puriﬁcation and quantiﬁcation of miRNA
The miRNA fraction was isolated using a miRNA isolation kit
(mirVana, Ambion, Austin, TX, USA) according to the manufacturer's
instructions. MiRNA was reverse-transcribed with the TaqMan
miRNA Reverse Transcription kit (Life Technologies) according to
the manufacturer's instructions.
MiR-21 (hsa-miR-21-3p), miR-29a (hsa-miR-29a-3p) and miR-29c
(hsa-miR-29c-3p) expression levels were quantiﬁed using the TaqMan
assay for miRNA and the TaqMan Universal Master Mix (both from Ap-
plied Biosystems, Carlsbad, CA, USA).MiR-U6Bwas used as endogenous
control for miR-21, miR-29a and miR-29c.
The expression of each miRNA in control and DMD ﬁbroblasts, myo-
blasts andmusclewas normalized to the expression ofmiR-U6B and de-
termined as the ratio of the target miRNA to the miR-U6B calculated by
2−ΔΔCt, where ΔΔCt = CtTarget − CtU6B. Quantitative PCR data were
expressed as “fold changes” relative to control levels expressed as 1.
Each analysis was performed in duplicate and repeated at least three
times with RNA from three different control and three different DMD
cell lines.
2.3. Real time PCR
Total RNAwas isolated fromﬁbroblasts,myoblasts andmuscle tissues
using TRI Reagent (Ambion) according to the manufacturer's instruc-
tions, and checked spectrophotometrically for quantity and purity using
a Nanodrop 2000C spectrophotometer (Thermo Scientiﬁc, Waltham,
MA, USA). RNA aliquots (1 μg) were reverse-transcribed in the presence
of 5× ﬁrst strand buffer (Life Technologies), 1 mM each deoxynucleoside
triphosphate, 8 pM random hexamers, 10 μM dithiothreitol, 1 IU/μl
RNAse inhibitor (Roche Molecular Biochemicals, Basel, Switzerland),
and 10 IU/μl M-MLV reverse transcriptase (Life Technologies) with incu-
bation at 37 °C for 1 h and at 95 °C for 5 min. The reaction product was
stored at−20 °Cpendinguse. cDNA integritywas assessed by PCR ampli-
ﬁcation of human glyceraldehyde-3-phosphate dehydrogenase (NM_
002046.5) with speciﬁc primers (forward 5′-GAAGGTGAAGGTCGGA
GTC-3′ and reverse 5′-GAAGATGGTGATGGGATTTC-3′). PCR conditions
were: 94 °C for 1 min, 54 °C for 1 min, and 72 °C for 1 min, for
35 cycles. Mouse cDNA integrity was assessed by PCR ampliﬁcation of
mouse actin (NM_009606.3) with speciﬁc primers (forward 5′-AGCCAT
GTACGTAGCCATCC-3′ and reverse 5′-CTCTCAGCTGTGGTGGTGAA-3′).
Human COL1A1 (Hs01076772_gH), COL3A1 (Hs00943809_m1),
COL6A1 (Hs01095579_g1), PTEN (Hs02621230_s1), SPRY-1
(Hs01083036_s1), FBN1 (Hs00171191_m1), YY1 (Hs00231533_
m1), PAI-1 (Hs01126604_m1, SERPINE), HMGA2 (Hs00971725_
m1), and TWF1 (Hs00702289_s1) transcripts; and mouse PTEN
(Mm00477208_m1), SPRY-1 (Mm01285700_m1) and ACTB
(4352341E) transcripts, were quantiﬁed by quantitative real time
PCR using TaqMan Universal PCR Master Mix and Assays-on-
Demand Gene Expression probes (Applied Biosystems). Reactions
were performed in 96-well plates with 25 μl volumes. Cycling
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40 cycles of PCR (15 s at 95 °C and 1 min at 60 °C). Products were de-
tected with the ABI Prism7000 sequence detection system (Applied
Biosystems).
The expression of each transcript in control and DMD ﬁbroblasts,
myoblasts and muscle was normalized to the expression of β-actin
and determined as the ratio of the target transcript to the β-actin tran-
script calculated by 2−ΔΔCt, where ΔΔCt= CtTarget− Ctß-actin. Quantita-
tive PCR data were expressed as “fold changes” relative to control levels
expressed as 1. Each real-time RT-PCR analysis was performed in dupli-
cate and repeated at least three times with RNA from three different
control and three different DMD cell lines.2.4. Transfection of miR-21 inhibitor and miR-29 mimic
5 × 105 cells (ﬁbroblasts or myoblasts) were seeded into six-well
plates and grown to 60% conﬂuence. Human hsa-miR-21
(MIMAT0004494) inhibitor, hsa-miR-29a (MIMAT0000086) and
hsa-miR-29c (MIMAT0000681) mimics (Life Technologies) and
controls (scrambled miRNAs) were allowed to form transfection
complexes with Lipofectamine RNAiMax transfection reagent (Life
Technologies) in Opti-MEM I Reduced SerumMedium (Life Technol-
ogies) at a ﬁnal concentration of 30 nM for 15 min at room tempera-
ture. After 24 h, the culture mediumwas changed; after 48 h samples
were either collected for extraction of mRNA and miRNAs, or cells
were analysed for immunocytochemistry and culture media
collected for further analyses. Transfection conditions were deﬁned
by preliminary tests using FAM dye-labelled miRNA random se-
quence (Applied Biosystems). The let-7c/HMGA2 (High Mobility
Group AT-hook 2) (Applied Biosystems) system was used as positive
control in ﬁbroblast miRNA inhibition experiments, while miR-1/
TWF1 (Applied Biosystems) system was used as positive control in
myoblast miRNA mimic experiments. After miRNA inhibitor let-7c
transfection, a signiﬁcant increase in mRNA levels of HMGA2was de-
tected in ﬁbroblasts; while after miRNA mimic miR-1 transfection, a
signiﬁcant decrease in TWF1 mRNA levels was detected in myo-
blasts, as expected (data not shown).2.5. Quantiﬁcation of soluble/extracellular collagen in cell cultures
Total soluble (non cross-linked) collagen was measured in superna-
tants from control andDMD ﬁbroblasts andmyoblasts, by a quantitative
dye-bindingmethod using the Sircol collagen assay (Biocolor, Belfast, N.
Ireland), according to the manufacturer's instructions. Protein concen-
tration in collected supernatants was determined using the DC Protein
Assay Reagent (Bio-Rad Laboratories, Hercules, CA, USA) and used for
normalization of soluble collagen.2.6. PAI-1 secretion and plasmin activity
PAI-1 secretion in cell cultureswas evaluated by ELISA (Life Technol-
ogies) following the manufacturer's instructions, before and after TGF-
β1 treatment, and after miR-21 inhibition.
Plasmin activity was measured indirectly in control and DMD ﬁbro-
blasts using the plasmin-speciﬁc chromogenic substrate D-Val-Leu-Lys
p-nitroanilide dihydrochloride (Sigma Aldrich). Culture supernatants
(35 μl) were incubated at 37 °C in a 96-well plate with 25 μl 0.1 M
Tris–HCl (pH 7.6) containing 2 mM EDTA and with 10 μl 1.5 mM chro-
mogenic substrate. P-nitroanilide release over 120 min was monitored
by measuring absorbance at 405 nm with a microplate reader (Victor
Wallac 1420, Perkin Elmer, San Diego, CA, USA). Plasmin activity was
normalized to cell number (determined by MTT assay, as described in
[56]) in each well.2.7. Immunocytochemistry
After ﬁxation in 4% paraformaldehyde for 30 min and perme-
abilization with 0.1% Triton-X 100 for 10 min, cells were incubated in
PBS containing 1% BSA for 30 min at room temperature, and overnight
at 4 °C with one of the following antibodies: mouse monoclonal anti-
PTEN (Sigma, 1:30 dilution), rabbit polyclonal anti-collagen I (Chemicon,
Millipore, Billerica, MA, USA; 1:150 dilution), mouse monoclonal anti-
collagen VI (Chemicon; 1:150 dilution) and rabbit polyclonal anti-PAI-1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:100 dilution). The
cells were then incubated in Alexa 488-conjugated goat anti-rabbit IgG
(for collagen I) or in Alexa 488-conjugated goat anti-mouse IgG (for
PTEN and collagen VI) (both diluted 1:2000, Life Technologies) for 2 h,
followed by DAPI (Sigma) 1:30,000 for 10 min. Cells were examined
under a Zeiss Axioplan ﬂuorescence microscope (Carl Zeiss AG,
Oberkochen, Germany) and pictures were takenwith the same exposure
settings.Muscle cryosectionswere incubated for 90min in anti-collagen I
or anti-collagen VI primary antibody, followed by incubation in Alexa
488-conjugated goat anti-mouse or anti-rabbit IgG, 1:2000, for 2 h.
Connective tissue extent was measured on collagen VI- and collagen I-
immunostained sections at ×20 magniﬁcation using the NIH Image
software version 1.62 (http://rsb.info.nih.gov/nih-image/), as previously
described [57].
2.8. Western blot
Fibroblasts transfected with miR-21 inhibitor were washed with PBS
and lysed in extraction buffer (10 mM Tris–HCl pH 7.4, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 0.5% Nonidet-P, 1% Triton X-100) containing
a protease inhibitor cocktail (Pierce Biotechnology, Rockford, IL, USA)
for 30 min on ice. The lysate was centrifuged (18,000 g, 15 min, 4 °C),
the supernatant collected, and its protein concentration determined
with DC Protein Assay Reagent (Bio-Rad). Aliquots containing 30 μg pro-
tein were solubilized in 2× Laemmli buffer (0.5 M Tris–HCl, pH 6.8, 20%
glycerol, 2% SDS, 5% 2-mercaptoethanol, 1% bromophenol blue), boiled,
separated by 4–10% SDS polyacrylamide gel electrophoresis (SDS-
PAGE), and transferred to nitrocellulose membranes (Schleicher and
Schuell, Keene, NH, USA). Membranes were probed with anti-PTEN
(mouse monoclonal, 1:500; Sigma), anti-Spry-1 (rabbit polyclonal,
1:250; Santa Cruz) anti-AKT (rabbit polyclonal, 1:300; Cell Signaling
Technology, Boston, MA, USA), and anti-pAKT (mouse monoclonal,
1:300; Cell Signaling Technology).
Extracellularly secreted collagen I was detected in culture medium.
Supernatant proteinswere separated on 4–10% SDS-PAGE. In the absence
of a reference standard (not available for extracellularly secreted pro-
teins) all lanes were loaded with equal amounts (40 μg) of total protein.
After separation biotin-conjugated secondary antibody was applied
(1:2500; Jackson ImmunoResearch), followed by peroxidase-conjugated
streptavidin (1:3000; Jackson ImmunoResearch), and detection with the
ECL chemiluminescence reagent (Amersham Biosciences).
2.9. Animals and experiments on mdx mice
C57BL/10ScSn-Dmdmdx/J mice were from Jackson Laboratory (Bar
Harbor, Maine, USA). Animal studies were approved by our review
board, in accordance with the Italian Health Ministry guidelines. Animal
care and use was in accordance with the Italian law and the EU directive
2010/63/EU. The animalswere housed in our facility under 12h light/12h
dark conditions with free access to food and water.
To knockdown miR-21 expression in three-month-old mdx mice
(5 per group), antagomiR-21 (5′-CCATCGACTGCTGTT-3′) or scrambled
(5′-ACGTCTATACGCCCA-3′) locked nucleic acid oligonucleotides
(Exiqon A/S, Vedbaek, Denmark) were injected intraperitoneally
(10 mg/kg in PBS) using a 26-gauge needle. Three injections were
given (day 1, 48 h after ﬁrst injection, and 15 days after ﬁrst injection).
Four weeks after ﬁrst injection, the animals were sacriﬁced by cervical
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moved, frozen in isopentane pre-cooled in liquid nitrogen, and main-
tained in liquid nitrogen pending use. Haematoxylin and eosin (H&E),
Gomori modiﬁed trichrome, acid phosphatase, and immunohistochem-
ical stainings were performed on consecutive 6–8 μm-thick cryosec-
tions. Numbers of acid-phosphatase-positive cells from highly
inﬂamed and mildly inﬂamed regions were counted on micrographs
of acid phosphatase-stained sections, as described inGibertini et al. [13].
Muscle ﬁbrosis was quantiﬁed on diaphragm preparations immuno-
stained to reveal collagens I and VI together. To block non-speciﬁc bind-
ing, sectionswere preincubated (30min)with 10% goat serum (Jackson
ImmunoResearch) in PBS, followed by incubation (2 h) with both anti-
collagen I (Chemicon, 1:40) and anti-collagen VI (Santa Cruz, 1:100)
polyclonals. Incubation (60 min) with Alexa 488-goat anti-rabbit IgG
(1:2000, Life Technologies) followed. As control, sections were incubat-
ed either with rabbit non-immune serum, or isotype-speciﬁc non-
immune IgG (Dako), or the primary antibodies were omitted. The area
of collagen immunostaining, as indicator of ﬁbrosis, was determined
at ×20 magniﬁcation as described [13]. Brieﬂy, 4 randomly selected
ﬁelds were photographed from each section and digitalized. Using the
software, the photographs were inverted and a threshold was applied
to obtain black and white images with areas positive for collagens in
black and negative areas in white. Manual corrections were sometimes
applied to eliminate non-muscle/non-ﬁbrosis areas or to add areas not
recognized by the software. The area positive for collagenswas calculat-
ed as a percentage of the entire image, and the mean percentage for
each group of animals calculated.2.10. Quantitation of soluble collagens in mdx diaphragm
Acid-soluble collagen concentration was determined in mouse dia-
phragms by the Sircol Collagen Assay (Biocolor), according to the
manufacturer's instructions. Brieﬂy, tissue samples were incubated
over-night at 4 °C in 0.5M acetic acid. 20 μl of samples' acid-soluble col-
lagens and reference standard were added to 200 μl of the colorimetric
reagent and gently mixed for 30 min, followed by centrifugation at
10,000 g for 10 min. To remove unbound dye a wash with ice-cold
Acid-Salt Buffer wash was performed. The SR dye was released from
the pellet with Alkali Reagent and colorimetric readings were taken in
duplicate at 550 nm. The amount of soluble collagens was expressed
as μg of collagens per mg of tissue.2.11. Statistical methods
Results were expressed as means and standard deviations (±). Dif-
ferences between DMD and control were assessed by the two-tailed
Student's t-test or one-way ANOVA with post-hoc Dunnett's test,
where appropriate. Differences in gene expression between cells treat-
ed and not treated with TGF-β1 were assessed using a mathematical
model based on PCR efﬁciency described by Pfafﬂ [36]. P values ≤ 0.05
were considered signiﬁcant. ELISA data were processed using a four-
parameter logistic model (Readerﬁt programme; http://www.
readerﬁt.com/). Each experiment, performed in duplicate or triplicate,
used separate cultures obtained from three DMD patients and three
controls.Fig. 1.MiRNA expression in cell cultures and muscle biopsies. Pearson's linear regression analy
lation between COLA1A transcript levels and patient age; (C) positive correlation between mi
transcripts; (E) positive correlation between miR-29a and COL1A1; and (F) positive correlati
age-matched control muscle (data from 14 patients and 11 controls) as determined by real ti
and (I) after TGF-β1 treatment. Fold changes are relative to miR-21 or miR-29 levels (expresse
in basal conditions and (K) after TGF-β1 treatment. Fold changes are relative tomiR-21 ormiR-2
to miR-U6B expression levels and are presented as means ± standard deviation (data from thAssociations of miRNA (miR-21, miR-29a, miR-29c) expression levels
with levels of collagen I and VI transcripts and proteins (considered
markers of ﬁbrosis, [61]), and patient age (considered an indicator of dis-
ease progression [18]), were assessed by Pearson's linear regression
analysis.3. Results
3.1. MiR-21 was increased and miR-29 decreased in DMD muscle; miR-21
was upregulated in DMD ﬁbroblasts, and miR-21, miR-29a and miR-29c
levels were downregulated in DMD myoblasts
In DMDmuscles, levels of miR-21 (6.95 ± 6.40, p b 0.001) were sig-
niﬁcantly higher, and levels of miR-29a (0.29 ± 0.12, p b 0.001) and
miR-29c (0.32 ± 0.15, p b 0.001) signiﬁcantly lower than in control
muscles (Fig. 1G). Similarly, in MDC1A muscles, levels of miR-21 were
signiﬁcantly higher (3.06 ± 0.54, p b 0.001), and levels of miR-29a
(0.10 ± 0.05, p b 0.001) and miR-29c (0.015 ± 0.007, p b 0.001) were
signiﬁcantly lower than in controls (not shown).
MiR-21 expression (R = 0.74, p b 0.05) (Fig. 1A) and COL1A1 mRNA
levels (R= 0.62; p b 0.05) correlated directly with patient age (Pearson's
linear regression, Fig. 1B). MiR-21 levels also correlated with COL1A1
(R = 0.91, p b 0.001) and COL6A1 mRNA levels (R = 0.69, p b 0.05)
(Figs. 1C, D), but not with the related proteins collagen I (R = 0.09,
p = 0.77) or collagen VI (R=−0.12, p = 0.51) (not shown), both eval-
uated as indicative of connective tissue extent.
MiR-29a correlated directly with both COL1A1 (R = 0.81, p b 0.05)
and COL6A1 (R = 0.81, p b 0.05) transcript levels (Figs. 1E, F). No corre-
lationwas found betweenmiR-29a and connective tissue extent evaluat-
ed by collagen I (R=0.37, p=0.23) and collagenVI (R=0.27, p=0.38)
immunostaining (not shown). No correlation was found between miR-
29c and COL1A1 (R = 0.18, p = 0.55) or COL6A1 (R = 0.03, p = 0.90)
transcript levels, or between miR-29c and connective tissue extent eval-
uated by collagen I (R=−0.36, p=0.22) and collagenVI (R=0.16, p=
0.58) immunostaining in muscle (not shown).
In ﬁbroblasts not treated with TGF-β1, miR-21 expression levels
were signiﬁcantly higher in DMD ﬁbroblasts (1.86 ± 0.37; p b 0.05)
than control ﬁbroblasts (expressed as 1). No differences in miR-29a
(0.95 ± 0.32, p = 0.94) or miR-29c (0.74 ± 0.18, p = 0.08) expression
were found in DMD compared to control ﬁbroblasts (Fig. 1H).
After TGF-β1 treatment miR-21 expression was signiﬁcantly higher
(2.11 ± 0.08, p b 0.001), and miR-29a (0.59 ± 0.13, p b 0.05) and
miR-29c (0.64 ± 0.06, p b 0.05) expression signiﬁcantly lower, in
DMD ﬁbroblasts compared to similarly treated control ﬁbroblasts
(Fig. 1I). There were no signiﬁcant differences between treated and un-
treated control ﬁbroblasts or between treated and untreated DMD
ﬁbroblasts.
As regardsmyoblasts not treated with TGF-β1,miR-21 (0.62± 0.23,
p b 0.05), miR-29a (0.46 ± 0.09, p b 0.001) and miR-29c (0.48 ± 0.19,
p b 0.05) levels were signiﬁcantly lower in DMDmyoblasts than in con-
trols (expressed as 1) (Fig. 1J).
After TGF-β1 treatment, mR-21 expression (1.1 ± 0.37, p = 0.67)
andmiR-29a (0.52± 0.33, p= 0.06) in DMDmyoblasts were no longer
signiﬁcantly lower than in controls, while miR-29c levels (0.45 ± 0.21,
p b 0.05) in DMD myoblasts remained signiﬁcantly lower than those
in controls (Fig. 1K). There were no signiﬁcant differences betweensis showing: (A) positive correlation between miR-21 and patient age; (B) positive corre-
R-21 and COL1A1 transcript levels; (D) positive correlation between miR-21 and COL6A1
on between miR-29a and COL6A1. (G) MiR-21, miR-29a and miR-29c levels in DMD and
me PCR. (H) MiR-21, miR-29a and miR-29c levels in DMD ﬁbroblasts in basal conditions
d as 1) in control ﬁbroblasts. (J) MiR-21, miR-29a and miR-29c levels in DMD myoblasts
9 levels (expressed as 1) in controlmyoblasts.MiR-21 andmiR-29 levelswere normalized
ree duplicated experiments for three cell lines of each cell type).
Fig. 2. Expression of target transcripts and ﬁbrosis related genes in cell cultures showing
that miR-21 targets are downregulated in DMD ﬁbroblasts; andmiR-29 targets are upreg-
ulated in DMD myoblasts. (A) Expression of miR-21 target transcripts PTEN and SPRY-1,
and of COL1A1 and COL6A1 in DMD ﬁbroblasts in basal conditions. Fold changes are rela-
tive to target transcript levels (expressed as 1) in age-matched control ﬁbroblasts.
(B) Expression of miR-29 target transcripts COL3A1, FBN1 and YY1, and of COL1A1 and
COL6A1, in DMD myoblasts in basal conditions. Fold changes are relative to target tran-
script levels (expressed as 1) in control myoblasts. Target transcript expression levels
are normalized to those of β-actin and presented as means ± standard deviations (data
from three duplicated experiments for three cell lines of each cell type).
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treated DMD myoblasts.
3.2. MiR-21 targets were downregulated in DMD ﬁbroblasts; and miR-29
targets were upregulated in DMD myoblasts
Search in the TargetScan or inmicroRNA database (www.targetscan.
org and http://www.microrna.org), detected putative miR-21 or miR-
29 binding sites in the untranslated regions of all the following target
genes: PTEN and SPRY-1, both targets of miR-21; COL3A1, FBN1 and
YY1, all targets of miR-29. These molecules have also been shown to
be targets of miR-21 or miR-29, respectively, by 3′-UTR luciferase
assay [28,43,44].
In DMD ﬁbroblasts not treated with TGF-β1, levels of PTEN
(0.60 ± 0.17, p b 0.05) and SPRY-1 (0.69 ± 0.06, p b 0.001) tran-
scripts were signiﬁcantly lower than in controls (expressed as 1),
while levels of COL1A1 (1.96 ± 0.35; p b 0.05) and COL6A1
(1.85 ± 0.64; p b 0.05) were signiﬁcantly higher than in control ﬁ-
broblasts (expressed as 1) (Fig. 2A). After TGF-β1 treatment, the
levels of these transcripts in DMD ﬁbroblasts did not change signiﬁ-
cantly compared to levels in untreated DMD ﬁbroblasts (not shown).
In DMD myoblasts not treated with TGF-β1, COL1A1 (1.63 ± 0.34,
p b 0.05) and COL6A1 (1.76 ± 0.35, p b 0.05) transcripts were signiﬁ-
cantly higher than those in untreated control myoblasts (Fig. 2B). Levels
of COL3A1, FBN1, and YY1, were also signiﬁcantly higher in untreated
DMD myoblasts than untreated controls (expressed as 1) (COL3A1:
2.09 ± 0.51, p b 0.05; FBN1: 1.68 ± 0.36, p b 0.05; YY1: 1.63 ± 0.15,
p b 0.001) (Fig. 2B). Following TGF-β1 treatment, levels of these tran-
scripts in DMD myoblasts did not change signiﬁcantly compared to
those in untreated DMD myoblasts (not shown).
3.3. Transfection of miR-21 inhibitor and miR-29 mimic respectively
lowered and increased miRNA levels
To further explore the effects of miRNAs in ﬁbroblasts and myo-
blasts, the cells were transiently transfected with either miR-21 inhibi-
tor or miR-29 mimics. Transfection efﬁciency was evaluated measuring
miRNA levels by RT-PCR.
Forty-eight hours after transfection,miR-21 levels were signiﬁcantly
lower in inhibitor-transfected DMD ﬁbroblasts than scrambled-
transfected DMD ﬁbroblasts: 0.38 ± 0.03 vs. 1.86 ± 0.37 (p b 0.05)
(Fig. 3A).
Forty-eight hours after transfection,miR-29a andmiR-29c levelswere
signiﬁcantly higher in mimic-transfected DMD myoblasts, than
scrambled-transfected DMDmyoblasts. Speciﬁcally, after miR-29a mim-
icking both miR-29a (13.18 ± 0.56 vs. 0.46 ± 0.11; p b 0.001) and miR-
29c (24.71 ± 6.21 vs. 0.46 ± 0.11; p b 0.05) were increased, and after
miR-29c mimicking both miR-29a (6.74 ± 0.24 vs. 0.48 ± 0.18;
p b 0.001) and miR-29c (37.48 ± 1.99 vs. 0.48 ± 0.18; p b 0.001) were
increased. The effects of both miR-29a and miR-29c mimics together on
transcription levels of miR-29a and miR-29c were also assessed. No sig-
niﬁcant differences in transcription levels of miR-29a and miR-29c after
double transfection compared to single transfection were observed
(miR-29a: 10.43 ± 1.8; miR-29c: 37.14 ± 6.00) (Fig. 3B).
3.4. MiR-21 inhibitor and miR-29 mimic transfection modulate target
transcripts
In DMD ﬁbroblasts, decreasing miR-21 levels by miR-21 inhibitor
transfection was sufﬁcient to induce upregulation of miR-21 target tran-
scripts and downregulation of ﬁbrosis related transcripts compared to
scrambled-transfectedDMDﬁbroblasts. Speciﬁcally,miR-21 silencing sig-
niﬁcantly increased PTENmRNA(2.01±0.69 vs. 0.6±0.17; pb 0.05) and
SPRY-1 mRNA (1.50 ± 0.23 vs. 0.69 ± 0.06; p b 0.05); and signiﬁcantly
decreased COL1A1 mRNA (0.40 ± 0.20 vs. 1.96 ± 0.35; p b 0.05) andCOL6A1 mRNA (0.60 ± 0.27 vs. 1.85 ± 0.64; p b 0.05) compared to
scrambled-transfected DMD ﬁbroblasts (Fig. 4A).
In DMD myoblasts, increasing miR-29 levels by transfection with
miR-29a and miR-29c mimics induced downregulation of miR-29 tar-
gets. Thus, after miR-29a mimicking, COL3A1 transcript levels were
0.52 ± 0.23 vs. 2.09 ± 0.51 in scrambled-transfected DMD myoblasts
Fig. 3. Transfection of miR-21 inhibitor in DMD ﬁbroblasts and miR-29 mimic in DMD
myoblasts respectively lowers and increases miRNA levels. (A) Signiﬁcant reduction in
miR-21 levels after miR-21 inhibition in DMD ﬁbroblasts (0.38 ± 0.03 vs. 1.86 ± 0.37;
p b 0.05) compared to scrambled-transfected DMD myoblasts. (B) Signiﬁcant increases
in miR-29a (13.18 ± 0.56 vs. 0.46 ± 0.11; p b 0.001) and miR-29c (24.71 ± 6.21 vs.
0.46 ± 0.11; p b 0.05) after transfection of miR-29a mimic, miR-29c mimic or both com-
pared to scrambled-transfected DMDmyoblasts. MiR-21 andmiR-29 levels were normal-
ized to those of miR-U6B and are presented as means ± standard deviations of data from
three duplicated experiments for three cell lines of each cell type.
Fig. 4. Effects on target transcripts and ﬁbrosis related genes of miR-21 inhibition in DMD
ﬁbroblasts andmiR-29mimicking in DMDmyoblasts. (A) Expression levels ofmiR-21 tar-
get transcripts PTEN and SPRY-1, and of COL1A1 and COL6A1 in DMD ﬁbroblasts after
miR-21 inhibition relative to expression levels in DMD ﬁbroblasts after transfection with
scrambled miRNA. (B) Expression levels of miR-29 target transcripts COL3A1, FBN1 and
YY1 in DMDmyoblasts after miR-29mimicking relative to expression levels in DMDmyo-
blasts after transfection with scrambled miRNA. (C) Expression levels of COL1A1 and
COL6A1 in DMD myoblasts after miR-29 mimicking. In all cases target transcript levels
were normalized to β-actin expression levels and data are presented asmeans± standard
deviations (data from three duplicated experiments for three cell lines of each cell type).
1457S. Zanotti et al. / Biochimica et Biophysica Acta 1852 (2015) 1451–1464(p b 0.05); FBN1 levels were 0.44± 0.29 vs. 1.63± 0.36 (p b 0.005); and
YY1 levels were 0.51 ± 0.37 vs. 1.68 ± 0.15 (p b 0.05). After miR-29c
mimicking COL3A1 levels were 0.25 ± 0.26 vs. 2.09 ± 0.51 (p b 0.05);
FBN1 levels were 0.70 ± 0.23 vs. 1.63 ± 0.36 (p b 0.05); and YY1 levels
were 1.08 ± 0.23 vs. 1.68 ± 0.15 (p b 0.05). After co-transfection of
miR-29a and miR-29c, COL3A1 levels were 0.35 ± 0.27 vs. 2.09 ± 0.51
(p b 0.05); FBN1 levels were 0.51 ± 0.28 vs. 1.63 ± 0.36 (p b 0.05);
and YY1 levels were 0.66 ± 0.27 vs. 1.68 ± 0.15 (p b 0.05). Results
using double miR-29 transfection did not differ from those obtained
with single transfection (Fig. 4B).
COL1A1 and COL6A1 transcript levels were also evaluated in DMD
myoblasts before and after miR-29 mimicking. In all conditions tested
(miR-29a, miR-29c, miR-29a plus miR-29c), both COL1A1 and COL6A1
mRNA levels were signiﬁcantly lower than in scrambled-transfected
DMD myoblasts. Thus, after miR-29a mimic, COL1A1 was 0.27 ± 0.11
vs. 1.63 ± 0.34 (p b 0.001); COL6A1 was 0.88 ± 0.08 vs. 1.76 ± 0.35
(p b 0.001). After miR-29c mimic, COL1A1 was 0.39 ± 0.23 vs. 1.63 ±
0.34 (p b 0.05); and COL6A1 was 0.57 ± 0.16 vs. 1.76 ± 0.35
(p b 0.001). After co-transfection of miR-29a and miR-29c, COL1A1 was
0.39 ± 0.30 vs. 1.63 ± 0.34 (p b 0.05); and COL6A1 was 0.58 ± 0.06 vs.
1.76 ± 0.35 (p b 0.001). Results using double miR-29 transfection did
not differ from those obtained with single transfection (Fig. 4C).3.5. MiR-21 inhibitor and miR-29 mimic transfection modulated
protein expression
PTEN was not detected by immunocytochemistry in scrambled-
transfected DMD ﬁbroblasts in basal conditions, but was expressed in
the cytosol after miR-21 inhibition. Both collagen I and collagen VI
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to scrambled-transfected DMD ﬁbroblasts (Fig. 5A). Collagen I and col-
lagen VI immunostaining was also clearly reduced in DMD myoblasts
after miR-29a and miR-29c mimicking, compared to scrambled-
transfected DMD myoblasts (Fig. 5B).
To determine whether PTEN is post-transcriptionally inhibited by
miR-21, PTEN protein expression was further assessed in DMD ﬁbro-
blasts byWestern blot. Amarked increase in PTEN protein after DMD ﬁ-
broblast transfection with miR-21 inhibitor was found compared to
scrambled-transfected DMD ﬁbroblasts, showing that PTEN is a direct
target of miR-21 (Fig. 5C). Since PTEN is a negative regulator of the
Akt/PI3-kinase pathway, Akt/PI3Kdownstreamsignallingwas also eval-
uated: it was found that phosphorylated-Akt (Ser473) was reduced
after miR-21 silencing in DMD ﬁbroblasts (Fig. 5C). Akt/PI3K signalling
has also been implicated in collagen production [24], so collagen I ex-
pression in DMD ﬁbroblast supernatants was evaluated. MiR-21 inhibi-
tion induced a decrease in collagen I expression compared to DMD
scrambled-transfected ﬁbroblasts (Fig. 5C). Spry-1 expression was also
increased in DMD ﬁbroblasts after miR-21 inhibition (Fig. 5C).Fig. 6.MiR-21 inhibitor andmiR-29mimic transfectionmodulate soluble collagen produc-
tion. (A) Collagenproduction in culturemedium from control andDMDﬁbroblasts in basal
conditions, after TGF-β1 treatment, and after miR-21 inhibition. (B) Collagen production
in culture medium from control and DMD myoblasts in basal conditions, after TGF-β1
treatment, and after miR-29 mimicking (data from three duplicated experiments for
three cell lines of each cell type). Soluble collagen in the supernatants was normalized
to total protein content.3.6. MiR-21 inhibitor and miR-29 mimic transfection modulated soluble
collagen production
Under basal conditions, soluble collagen production was signiﬁcantly
greater in the culturemediumofDMDﬁbroblasts than inmediumof con-
trol ﬁbroblasts (237.71± 12.88 μg/ml vs. 135.53± 1.49 μg/ml; p b 0.05).
TGF-β1 treatment induced a further signiﬁcant increase in soluble colla-
gen production in DMD ﬁbroblasts only (385.83 ± 38.47 μg/ml,
p b 0.05). MiR-21 silencing induced a signiﬁcant reduction in soluble col-
lagen production both in DMD (35.94±10.69 μg/ml; p b 0.001) and con-
trol ﬁbroblasts (44.41 ± 19.25 μg/ml; p b 0.05) compared to medium
from scrambled-transfected cells (Fig. 6A).
Under basal conditions soluble collagen productionwas signiﬁcantly
higher in culturemedium of DMDmyoblasts than controlmyoblastme-
dium (131.73 ± 18.91 μg/ml vs. 37.02 ± 0.92 μg/ml; p b 0.05). TGF-β1
treatment had no signiﬁcant effects. Only transfection of control myo-
blasts with miR-29c mimic induced a signiﬁcant reduction in soluble
collagen production compared to scrambled-transfected control myo-
blasts (19.89 ± 4.66 μg/ml vs. 37.02 ± 0.92 μg/ml; p b 0.05). In DMD
myoblasts, by contrast, signiﬁcant reductions in collagen production oc-
curred after miR-29a (55.63 ± 13.56 μg/ml; p b 0.05), miR-29c
(67.46 ± 7.23 μg/ml, p b 0.05) and miR-29a plus miR-29c mimic trans-
fection (48.77 ± 6.58 μg/ml; p b 0.05) compared to scrambled-
transfected myoblasts (131.73 ± 40.12 μg/ml) (Fig. 6B).3.7. PAI-1/plasmin were downregulated by miR-21 inhibition in
DMD ﬁbroblasts
Transcript levels of PAI-1were signiﬁcantly higher in DMD ﬁbroblasts
(2.19 ± 0.12) than control ﬁbroblasts (p b 0.001), and increased further
after TGF-β1 treatment (2.42± 0.22, p b 0.001). No signiﬁcant difference
between basal DMD ﬁbroblasts (not treated with TGF-β1) and TGF-β1-
treated ﬁbroblasts was observed. PAI-1 transcript levels were signiﬁcant-
ly lower in DMD ﬁbroblasts after miR-21 silencing compared to control
ﬁbroblasts (0.34 ± 0.27 vs. 2.19 ± 0.12; p b 0.05; Fig. 7A).Fig. 5. Immunolocalization of target proteins aftermiR-21 inhibition inﬁbroblasts andmiR-29m
is present in the cytosol after transfection with miR-21 inhibitor, but is not present in DMD ﬁbr
collagen VI (Alexa Fluor 488 dye, green) positivity is lower in DMD ﬁbroblasts transfected with
(B) Staining for collagen I and collagen VI (Alexa Fluor 488 dye, green) is lower in DMDmyobl
miRNA. Nuclei stained with DAPI (blue). Scale bar = 20 μm. (C) Representative Western blots
and decreased expression of phosphorylated Akt; and of ﬁbroblast cell culture supernatants shPAI-1 proteinwas expressed in a punctate pattern in the nucleus and
cytoplasmof DMDﬁbroblasts in basal conditions; aftermiR-21 silencing
positivity decreased in both compartments (Fig. 7B).
PAI-1 production was signiﬁcantly higher in basal conditions in DMD
ﬁbroblasts (965.08 ± 37.82 pg/ml) than control ﬁbroblasts (261.53 ±
53.99 pg/ml; p b 0.05). TGF-β1 treatment induced a signiﬁcant increase
in PAI-1 production both in DMD (4638.11 ± 143 pg/ml; p b 0.05) and
control (3602.75 ± 297 pg/ml; p b 0.05) ﬁbroblasts, compared to un-
treated cells. MiR-21 silencing in DMD ﬁbroblasts signiﬁcantly reduced
PAI-1 production (437.88 ± 132 pg/ml vs. 965.08 ± 37.82; p b 0.001)
compared to DMD ﬁbroblasts under basal conditions (Fig. 7C).
The enzymatic activity of plasmin was signiﬁcantly lower in
DMD ﬁbroblast culture medium than control ﬁbroblast medium
(3.37 ± 0.46 ng substrate/min vs. 10.29 ± 4.58; p b 0.05). Plasmin
activity signiﬁcantly increased in DMD ﬁbroblast medium afterimicking inmyoblasts. (A) InDMD ﬁbroblasts PTEN (Alexa Fluor 488 dye, green) positivity
oblasts transfectedwith scrambledmiRNA. Nuclei stained with DAPI (blue). Collagen I and
miR-21 inhibitor than ﬁbroblasts transfected with scrambled miRNA. Scale bar = 20 μm.
asts after miR-29 mimicking, than staining in DMDmyoblasts transfected with scrambled
of DMD ﬁbroblast cell extracts showing increased expression of PTEN and Spry-1 proteins
owing collagen I decrease after miR-21 inhibition. NT = not treated.
Fig. 7. PAI-1/plasmin are downregulated bymiR-21 inhibition in DMD ﬁbroblasts. (A) Expression levels of PAI-1 transcripts in DMD ﬁbroblasts in basal conditions, after TGF-β1 treatment
and after miR-21 inhibition. Fold changes are relative to PAI-1 levels (expressed as 1) in control ﬁbroblasts, and are normalized to β-actin expression presented as means± standard de-
viation (data from three duplicated experiments for three cell lines of each cell type). (B) PAI-1 protein (Alexa Fluor 488 dye, green) is evident as punctate positivity in the nucleus and
cytoplasm of DMD ﬁbroblasts in basal conditions. AftermiR-21 silencing positivity is reduced in both nucleus and cytoplasm. Nuclei stainedwith DAPI (blue). Scale bar=20 μm. (C) PAI-1
protein levels determined by ELISA inmedium from control and DMD ﬁbroblasts in basal conditions and after TGF-β1 treatment (data from two duplicated experiments for three cell lines
of each cell type), and after miR-21 inhibition (data from two duplicated experiments for three cell lines of each cell type). (D) Quantiﬁcation of plasmin activity in supernatants from
control and DMD ﬁbroblasts in basal conditions and from DMD ﬁbroblasts after miR-21 inhibition (data from two duplicated experiments for three cell lines of each cell type).
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pared to untransfected DMD ﬁbroblasts (Fig. 7D).
3.8. AntagomiR-21 treatment reduced muscle ﬁbrosis in mdx mouse
diaphragm
Histological evaluation of diaphragmmuscle ofmdxmice treatedwith
antagomiR-21 showed that the morphology was better organized than
scramble-treated diaphragms (Figs. 8A, B). Numbers of acid phosphatase
positive cells did not differ signiﬁcantly between, respectively, highly or
mildly inﬂamed regions of muscles from antagomiR-21-treated, and
highly or mildly inﬂamed regions of muscles from scramble-treated
mice (not shown). Assessment of miR-21 targets in diaphragm showed
that PTEN (2.25±0.81; pb 0.01) and SPRY-1 (1.61±0.82; pb 0.05) tran-
script levels were signiﬁcantly higher in antagomiR-21-treated compared
to scramble-treated diaphragms (expressed as 1) (Fig. 8E). Immunostain-
ing of diaphragm showed that collagen I and collagen VI were present in
the perimysium and endomysium and that areas of collagen I/collagen VI
positivity (Figs. 8C,D) were signiﬁcantly lower in antagomiR-21-treated
(19.02 ± 2.71% area) than scramble-treated diaphragms (22.56 ± 4.41%
area; p b 0.01) (Fig. 8F).
Assessment of soluble collagens extracted from the diaphragm of
treated and untreated animals revealed that collagens were signiﬁcant-
ly reduced in antagomiR-21-treated than scramble-treated diaphragms
(41.42 ± 5.04 vs. 48.8 ± 4.86 μg/mg of tissue; p b 0.05) (Fig. 8G).
4. Discussion
Our extensive investigations of miR-21 and miR-29 on DMDmuscle
and muscle-derived cells, show that miR-21 is upregulated in DMD
muscles and ﬁbroblasts and miR-29 is downregulated in DMDmuscles
and myoblasts, with corresponding proﬁbrotic alterations in target
transcript and protein expression. OurmiRNA inhibition andmimicking
experiments directly implicate miR-21 and miR-29 in ﬁbrosis-relatedalterations of target transcript and protein expression, and in increased
production of ECMproteins and other proﬁbroticmolecules. Overall our
data show that these miRNAs have fundamental but opposing roles in
regulating ﬁbrosis in skeletal muscle (Fig. 9).4.1. MiR-21 upregulation and its implications
We found that miR-21 was upregulated in DMD muscle, and that
levels correlated directly with COL1A1 and COL6A1 transcript levels
(markers of ﬁbrosis, [61]) and also age (marker of disease progression
[18]).
MiR-21 upregulation in DMD muscle and ﬁbroblasts, together with
upregulation of collagen, downregulation of known miR-21 targets in-
volved in ﬁbrogenesis, and interaction with TGF-β1, all strongly impli-
cate this miRNA as a major player in DMD ﬁbrosis. We also found that
miR-21 is upregulated in highly ﬁbrotic muscle biopsies from MDC1A
patients, implying that miR-21 is involved in muscle ﬁbrosis in general.
These ﬁndings are fully consistent with recent data showing that
miR-21 is upregulated in ﬁbrosis of lung, heart, liver and kidney [6,12,
23,32], while increased levels of miR-21 in ﬁbroblasts have been
found in several other conditions. Thus, Thum et al. [43] showed that
miR-21 was weakly expressed in normal myocardium, but after infarc-
tion miR-21 levels increased in cardiac ﬁbroblasts, in direct correlation
with increased atrial collagen content and reduced SPRY-1 expression.
Roy et al. [38] found increased miR-21 levels in murine cardiac ﬁbro-
blasts during heart remodelling after induced myocardial infarction,
and identiﬁed PTEN as a direct target of miR-21. In liver ﬁbrosis, miR-
21 is also upregulated and has been shown to activate stellate cells via
PTEN/Akt signalling. Stellate cells are liver-speciﬁc and play fundamen-
tal roles in several biological and pathological processes including
ﬁbrogenesis [50].
The results of our miR-21-silencing experiments in DMD ﬁbroblasts
provide further evidence of miR-21 involvement in DMD ﬁbrosis, since
Fig. 8. AntagomiR-21 treatment reduces muscle ﬁbrosis in mdx mouse diaphragm. H&E stained sections of diaphragm from an antagomiR-21-treated (A) and a scramble-treated
(B) mouse, showing that histopathologic features are less severe in the former. Immunostaining of collagen I and VI on sections of diaphragm from an antagomiR-21-treated (C) and a
scramble-treated mouse (D) showing decreased ﬁbrosis in the former. Scale bar = 50 μm. (E) Transcript quantitation of miR-21 targets PTEN and SPRY-1, (F) quantitation of ﬁbrosis
and (G) soluble collagen determination in antagomiR-21 and scramble-treated mice. Levels of PTEN and SPRY-1 are signiﬁcantly greater, and ﬁbrosis is signiﬁcantly reduced in
antagomiR-21 treated diaphragm.
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their downregulation is due to miR-21.
PTEN is a key regulator of the cell cycle, cell motility and apoptosis
[51]. During normal tissue repair, PTEN upregulation due to ECM con-
traction induces inhibition of the Akt/PI3-kinase pathway and triggers
ﬁbroblast apoptosis and termination of the repair process [31]. In ﬁbrot-
ic conditions, reduction of PTEN expression increases Akt/PI3-kinase
signalling and hence ﬁbroblast proliferation and viability, thereby
favouring increased ﬁbrosis [33]. In DMD ﬁbroblasts we found that
miR-21 upregulation was associated with reduced PTEN expression
(transcript and protein) and Akt pathway activation (Western blot of
phosphorylated Akt),whilemiR-21 silencing rescued PTEN and reduced
Akt activation. We also found that miR-21 silencing reduced collagen I
protein expression, probably in relation to reduced Akt activation. Lu
et al. [24] demonstrated that in human lung ﬁbroblasts the Akt/PI3K
pathway is involved in collagen production and ﬁbroblast proliferation,
while more recently He et al. [17] demonstrated that PTEN overexpres-
sion in lung ﬁbroblasts suppresses collagen I production by inhibiting
the Akt/PI3K pathway. Bujor et al. [7] also found that activated Akt hasproﬁbrotic effects in dermal ﬁbroblasts, promoting collagen synthesis
and reducing MMP-1 activity.
As regards SPRY-1 transcripts, their expression is reduced in failing
heart, resulting in increased levels of extracellular signal-regulated ki-
nases (ERK), which contribute toﬁbroblast survival and to interstitial ﬁ-
brosis [43]. So, reduced expression of this target for miR-21 appears to
promote ﬁbrosis and is also consistent with our previous ﬁnding that
the ERK pathway is upregulated in the same cells [54]. We also found
thatmiR-21 inhibition in DMD ﬁbroblasts induced increased expression
of SPRY-1 protein.
4.2. MiR-21 and TGF-β1
TGF-β1 has an established role in ﬁbrosis. Increased levels of TGF-
β1 in DMD muscle had been reported previously by our group and
others [4,15,26,57]. In the present study we found that treatment
of ﬁbroblasts with TGF-β1 resulted in increased miR-21 levels. This
is interesting in light of previous studies [6,53] showing that miR-
21 downregulation inhibits TGF-β1-induced transdifferentiation of
Fig. 9. Scheme summarizing our ﬁndings on inﬂuences of miR-21 andmiR-29 on ﬁbroticmechanisms in DMD ﬁbroblasts andmyoblasts. ↑: upregulation, ↓: downregulation,⊥: inhibition.
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transdifferentiation. Myoﬁbroblasts are principally responsible
for increased collagen synthesis in DMD and other ﬁbrotic
conditions [29].
4.3. The PAI-1/plasmin system
In view of our ﬁnding [54,55] that muscle-derived ﬁbroblasts from
DMD patients are ﬁbrogenic, we investigated the PAI-1/plasmin system
in ﬁbroblasts. This system, in addition to being a negative regulator of
the proteolytic activity of plasmin, is also involved in ﬁbrosis and the
regulation of miR-21 biogenesis [3]. We found signiﬁcantly upregulated
PAI-1 transcript and protein levels in DMD ﬁbroblasts – further in-
creased by TGF-β1 treatment – with consequent signiﬁcant reduction
in plasmin activity, suggesting that PAI-1 is directly involved in altered
ECM homeostasis in DMD. PAI-1 is also linked to miR-21, since we
found that miR-21 inhibition in DMD ﬁbroblasts caused a signiﬁcant re-
duction in PAI-1 mRNA levels and a signiﬁcant increase in plasmin
activity.
4.4. MiR-21 downregulation as anti-ﬁbrotic therapy
Our ﬁndings therefore suggest miR-21 inhibition as a possible ap-
proach to reducing ﬁbrosis, since inhibition not only has an antiﬁbrotic
effect on known target transcripts, but also an antiﬁbrotic regulatory ac-
tion on the PAI-1/plasmin system. Previous data also indicate that miR-
21 inhibition can reduce ﬁbrosis. Thus in a mouse cardiac hypertrophy
model, miR-21 silencing inhibited interstitial ﬁbrosis [43]; miR-21 anti-
sense probes diminished the severity of induced lung ﬁbrosis in mice
and attenuated the pro-ﬁbrogenic activity of TGF-β1 in ﬁbroblasts
[23]; and antagomiR-21 injection prevented ﬁbrosis in a mouse model
of heart infarction [1]. Our experiments on mdx mice showed that
antagomiR-21 treatment effectively reduced not only levels of target
transcripts but also extent of ﬁbrosis and soluble collagen production.
These effects were evident only a month after treatment at lowest
dose reported effective in the literature [14,25,35]. Thus miR-21 silenc-
ing shows promise as an anti-ﬁbrosis therapy. Other miRNAs have beenshown to be importantmodulators of the dystrophic phenotype. For ex-
ample, Cordani et al. [8] recently showed that nitric oxide-induced up-
regulation of miR-27 was able to inhibit adipogenesis, which is an
integral part of the ﬁbrotic process.
4.5. MiR-29 downregulation and its implications
The miR-29 family comprises miR-29a, miR-29b and miR-29c that
have similar sequences, expression patterns and functions [21]. MiR-
29s are known to suppress ﬁbrosis by suppressing the expression of
various ECM components [19]. Reduced miR-29 expression has been
implicated in the development of ﬁbrosis in liver, kidney, lung and
heart [16].
Our ﬁndings showing that miR-29a and miR-29c expression is re-
duced in DMDmuscle biopsies andmyoblasts (and also in highly ﬁbrotic
muscle biopsies from MDC1A patients), and that miR-29a and miR-29c
mimicking in DMDmyoblasts results in modulation of target transcripts
involved in ﬁbrosis [44], suggest that miR-29 upregulation may be a use-
ful mitigation strategy in advanced disease when myoblasts are produc-
ing greater quantities of ECM components (normally ﬁbroblasts are the
main producers of ECM components).
As well as acting as an anti-ﬁbrogenic regulator, miR-29 also pro-
motes myogenesis by directly inhibiting YY1, a negative regulator of
muscle genes [46]. Thus, muscle regeneration inhibited by upregulation
of YY1 was reversed by miR-29 upregulation [49]. Our ﬁndings that
miR-29 downregulation and YY1 upregulation in DMD myoblasts in
basal conditions were reversed after miR-29 mimicking, are in agree-
ment with those of Wang et al. [49].
5. Conclusions
Ardite et al. [3] showed that miR-21 is involved in DMD ﬁbrosis,
while Wang et al. [47] showed that miR-29 is involved in ﬁbrosis in
the mdx mouse. Our data amplify these ﬁndings by showing that miR-
21 is upregulated in DMDmuscles and ﬁbroblasts andmiR-29 is down-
regulated in DMD muscles and myoblasts, with corresponding
proﬁbrotic alterations in target transcript and protein expression.
1463S. Zanotti et al. / Biochimica et Biophysica Acta 1852 (2015) 1451–1464Importantly we also show that miR-21 inhibition and miR-29 mimick-
ing in ﬁbrogenic and myogenic cells from DMD patients directly impli-
cate miR-21 and miR-29 in proﬁbrotic alterations of target transcript
and protein expression, as well as the increased production of several
ECM proteins. Taken together these ﬁndings show that miR-21 and
miR-29 have fundamental but opposing roles in regulating ﬁbrosis in
skeletal muscle.
Finally our studies on mdx mice indicate that miR-21 inhibition has
promise as an agent for contrasting muscle ﬁbrosis. In general miRNA
modulators can be administered easily, have long duration of action
(up to 6 weeks in mice), are well tolerated, modulate miRNAs in most
organs [34] and havemore selective actions than the various pleiotropic
molecules proposed as anti-ﬁbrotic agents so far [2,45,60]. Effective
miRNA mimics have become available for whole animal use only very
recently. Montgomery et al. [30] in their study have shown that miR-
29 mimics decrease collagen expression and block and reverse
bleomycin-induced pulmonary ﬁbrosis. Our study suggests that a com-
bination of miR-21 inhibition andmiR-29 upregulation could be a more
effective strategy for treating muscle ﬁbrosis.
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